For patients with HA and frequent bleeding (mostly severe hemophilia), standard care involves regular prophylactic intravenous infusions of factor VIII (FVIII) to maintain FVIII activity levels of ≥1 U/dL, preventing bleeding and long-term complications. The gene discussed is F8; the disease is hemophilia.